A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
NCT02435121
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
1
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm Malignant
Interventions
DRUG:
SAR125844
Sponsor
Sanofi